Should You Be Excited for Regeneron (REGN)?

3 days ago 3

Soumya Eswaran

Tue, January 20, 2026 astatine 7:28 AM CST 3 min read

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Fund returned 3.35% successful the quarter, compared to the S&P 500’s 2.66% and the Russell 1000 Value Index’s 3.81% return. 2025 was a challenging twelvemonth for the firm, arsenic it did not person immoderate standout performers. Approximately 5% of the portfolio gained 20% oregon more, portion 35% of the S&P 500 deed that level. The wide marketplace dynamic drove the Fund’s underperformance. The steadfast focuses connected actions to fortify portfolio outcomes alternatively than chasing winners astatine the incorrect time. The steadfast reiterates that gathering a portfolio of existent companies connected discourtesy successful a play of excessive speculation volition payment each markets. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Longleaf Partners Fund highlighted stocks specified arsenic Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Headquartered successful Tarrytown, New York, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is simply a biotechnology company. On January 16, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) banal closed astatine $733.04 per share. One-month instrumentality of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was -5.94%, and its shares gained 7.55% of their worth implicit the past 52 weeks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has a marketplace capitalization of $77.693 billion.

Longleaf Partners Fund stated the pursuing regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) successful its 4th fourth 2025 capitalist letter:

"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Healthcare institution Regeneron was a detractor successful the archetypal fractional of the twelvemonth but ended up arsenic a contributor for the 4th and afloat year. It did not initially consciousness great, but our phased buy-in has worked good truthful far. We proceed to similar the company’s beardown presumption successful allergic diseases (DUPIXENT) and oncology (LIBTAYO and others). We judge the marketplace focuses excessively overmuch connected EYLEA, a retinal illness medicine which is little than 20% of the company's value. The institution has a nett currency equilibrium expanse and large owner-partners. Unlike astir others successful its industry, it has sworn disconnected ample M&A and was a worldly stock repurchaser successful 2025. We inactive are not paying overmuch (or thing depending connected however you bash the math) for the company’s sizeable pipeline value. After immoderate archetypal pipeline disappointment successful the archetypal portion of the year, determination were much positives arsenic the twelvemonth went on. The P/V remains low, and we are excited for Regeneron to beryllium a meaningful presumption entering the year."